Association of adverse events (AEs) with efficiacy outcomes for Cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase 3 CELESTIAL trial

Authors
Category Primary study
JournalOncology Research and Treatment
Year 2019
This article has no abstract
Epistemonikos ID: 3fab46d1bc12d026331e4ecf6fce24799c933a30
First added on: Nov 21, 2025